PDF
Hamlet: Neutraceutical Patent granted in Europe
Hamlet Pharma AB has secured patent protection in Europe for milk-based nutraceutical products that have been prepared using a mild process that generates nutraceutically beneficial complexes. This is the subject of European patent EP 3295953 B1. The patent is valid until August 8, 2033.
The patent is based on extensive academic research and discoveries made by researchers at Lund University. With this patent, Hamlet Pharma AB continues to expand it's intellectual property portfolio to cover further areas where its key products show benefit.
`Bamlet is a molecule with beneficial effects. Through a neutraceutical preparation, Bamlet will reach consumers who can benefit from these effects " says Catharina Svanborg, CMO and chairman of the board of Hamlet Pharma Ltd.
"We are very proud that this patent has been granted in Europe" says Mats Persson, CEO of Hamlet Pharma Ltd.
This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-11-2020 14:58 CET.